posted
Got in today at .30 - Got filled in 3 parts: 7K, 2K and 1K for a total of 10K.
I'll actually ADMIT I bought because of an Email Alert (I did do 5 min. of DD to make sure it wasn't just another pinkie scam). Here it is - and I hope they keep it up until we hit $1.50 !! (Made a killing on ONCY - VERY similar cancer drug) 3 years ago:
Ken Coleman’s readers recently made 138% in 25 days, 665% in four months ... and now …
PYTO has potential to be the most profitable stock you ever buy.
A cancer drug that double-binds to cancer cells.
Potential gains of 500% in 90 days.
Fellow Investor
The message you’re reading is different than any I’ve ever sent.
You may have seen me write about PhytoMedical Technologies (PYTO) recently, as the #1 stock I’m recommending today.
PhytoMedical just released more news about their breakthrough cancer-killing technology, and it’s important enough to repeat here.
The news announces that…
“Research outcomes from ongoing in vitro studies of the Company’s sponsored anti-cancer compounds have successfully demonstrated the ability to kill a strain of human brain cancer cells which is otherwise highly-resistant to currently available drugs.”
In other words, they have scientific proof that the drug they’re developing kills brain cancer cells of the most deadly kind.
What’s more, it works in a novel new way that could potentially be an entirely new class of class of drug that has only been dreamed of before.
And that could translate to millions in profits for early investors.
Science has searched for the holy grail of cancer treatment for 60 years, but till now every method to treat cancer at the molecular level has failed at one critical point – the ability of the drugs to bind firmly to the diseased DNA.
Investors flock to any sign that a new medical innovation may be moving toward commercialization, and cancer stocks often move highest.
And now this historic news from PhytoMedical Technologies (PYTO) could rocket the stock to huge gains.
Now, I expect PYTO to surge 500% or more in 90 days.
Here’s why….
Buy on news, hold on for fast gains.
When you get in early, just at the point of positive news, you can pocket riches on cancer-related stocks.
One pharmaceutical stock shot up 280% in the first 14 days of December after announcing that one of their technologies showed positive results.
Just a few months ago, in July 2007, one tiny cancer research company with a $7 million market cap nearly tripled after its progress was profiled in two leading biotech publications.
A month before that another shot up 176% in less than a month, from $1.26 to $3.48, on positive results of its preclinical studies.
And earlier in the year, yet another cancer-related stock scored 65% gains in 23 days just on news of a different cancer-related stock!
And after announcing positive clinical results for its own cancer drug, the stock nearly doubled.
Another rocketed 120% in the last five and a half months of 2007 – and 5,320% in the last five years.
The secret to gains like these is to get in at the right time.
And NOW is the right time for PYTO – I’m projecting a potential for 500% or more in 90 days because of the current low price of the stock and the importance of their research.
For details on PYTO’s cancer research, including the exciting new developments that could mean the first new class of cancer drug in 50 years, pushing huge stock gains today, you can see them here.
I strongly suggest that you consider investing in PYTO today.
Sincerely,
Ken Coleman
Publisher, The Investment Tracker
Ken Coleman's Investment Tracker subscribers are up 66.79% per year average over the past 4 years. He is a former member of the Senate Select Committee on Federal Reserve Policy, and his show is syndicated nationally on TNN.
View Report Note: To ease your concerns about potential download viruses, this is a website link, not a PDF download.
Disclaimer: Kenneth Coleman's Investment Tracker is an independent paid circulation newsletter. This paid advertising issue of the Investment Tracker does not purport to provide an analysis of any company's financial position or prospects and this is not to be construed as a recommendation by the Investment Tracker and is not in any way to be construed as an offer or solicitation to buy or sell any security. The Investment Tracker did not receive compensation with respect to the writing of this special report, however the Investment Tracker expects to generate new subscriber revenue, the amount of which is unknown at this time, to its newsletter through the distribution of this advertising piece. The costs associated with the distribution of this report in the amount of $16,800 was paid for by Cogito Corp., an independent investor relations agency retained by PhytoMedical Technologies, Inc. (PhytoMedical) to build investor and industry awareness for PhytoMedical and to generate subscription revenues for the Investment Tracker. Cogito Corp. has been retained by PhytoMedical on a month to month basis and receives a monthly fee of $7,250, plus all expenses, including the distribution costs of this report. PhytoMedical's financial position and all information should be verified with the company. The Investment Tracker presents information in this report believed to be reliable, but its accuracy cannot be guaranteed. The information provided in this advertisement is not intended for distribution to residents of British Columbia, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. Past performance does not guarantee future results. The information contained herein contains forward-looking statements and information within the meaning of Section Twenty-Seven A of the Securities Act of Nineteen Hundred Ninety-Three and Section Twenty-One E of the Securities Exchange Act of Nineteen Hundred Thirty-Four. In accordance with safe harbor provisions of the Private Securities Litigation Reform Act of Nineteen Hundred Ninety-Five, the statements contained herein that look forward in time, which include other than historical information, involve risks and uncertainties that may affect actual results of operations. The Investment Tracker makes no commitment to publicly release the results of any revisions to these projected statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a full version of this disclaimer, please click here: Full Disclaimer
If you do not wish to receive further email contact from PhytoMedical Technologies, Inc. please click here
stevea1427*aol.com: We do not endorse the foregoing, and we assume no responsibility for the purchase and/or use thereof. MarketFN.com has no affiliation and is not recommending the mentioned stock. We have not independently confirmed the accuracy, correctness, or truthfulness of the statements and opinions that the advertiser has expressed above or in any related reports. We encourage you to verify all claims contained in the above advertisement and to investigate the company or investment opportunity. Our very limited research, which should not be relied on, has found that the above-mentioned company's independent auditors has issued a going concern opinion. You are hereby advised that Online Investment Services, LP ("OIS") (owner of MarketFN.com) is receiving a cash fee of fourteen thousand dollars for the distribution of this email. The company is not affiliated with OIS. Please read the full disclosure here. You may review our Privacy Policy. If you no longer wish to receive this newsletter, please unsubscribe now. 1153 Bergen Pkwy, Suite M502, Evergreen, CO 80439
Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
